LONDON, UK / ACCESSWIRE / January 03, 2018 / Active-Investors.com has just released a free research report on Becton Dickinson & Co. (NYSE: BDX) ("BD"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BDX as the Company’s latest news hit the wire. On December 29, 2017, the Company announced that it has completed the acquisition of C. R. Bard, Inc. ("Bard"), creating a new health care industry leader with approximately $16 billion in annualized revenue. Register today and get access to over 1000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Becton Dickinson most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=BDX
Terms of the Transaction
Upon completion of the acquisition, Bard will become a wholly-owned subsidiary of BD. Each outstanding share of Bard common stock was converted to the right to receive $222.93 in cash without interest, and 0.5077 of a share of BD common stock. Following the acquisition, Bard’s shareholders will own approximately 15% of the combined Company. Bard’s shares will cease trading and will be delisted from the New York Stock Exchange.
Strategic Benefits
The combined Company will improve both the treatment of disease for patients and the process of care for healthcare providers. Bard’s strong product portfolio and innovation pipeline will increase BD’s opportunities in fast-growing clinical areas, and the combination will enhance growth opportunities for the combined Company in non-US markets. The acquisition will further expand BD’s leadership in infection prevention, with offerings positioned to address 75% of the costliest and frequent healthcare-associated infections. It is likely to create new opportunities to build on BD’s leadership position in medication management and infection prevention with an expanded offering of solutions across the care continuum.
Transaction Likely to Generate Low-Single Digit Accretion to Adjusted EPS in 2018
BD expects the transaction to generate low-single digit accretion to adjusted earnings per share (EPS) in the fiscal year 2018, and high-single-digit accretion in the fiscal year 2019. Except for transaction-related expenses, the acquisition will not have a material impact on BD’s financial results in the first quarter of the fiscal year 2018 ending December 31, 2017. Approximately $300 million of estimated annual, pre-tax, run-rate cost synergies are expected by the fiscal year 2020.
Approvals by Regulatory Bodies
On December 22, 2017, BD received clearance by the US Federal Trade Commission (FTC) to acquire Bard. BD also received clearance by the Ministry of Commerce of the People’s Republic of China (MOFCOM) for the acquisition on December 28, 2017. The clearances were contingent on the divestitures of BD’s soft tissue core needle biopsy product line and Bard’s Aspira® product line of tunneled home drainage catheters and accessories.
Acquisition Initially Announced in April 2017
The acquisition was announced on April 23, 2017. BD announced a definitive agreement to acquire Bard for a total consideration of $24 billion. The agreement was unanimously approved by the Boards of Directors of both Companies. The transaction was subject to regulatory and Bard’s shareholders approvals, and customary closing conditions. In August 2017, Bard’s shareholders approved the proposed merger.
BD’s Acquisition of Caesarea Medical Electronics
On April 04, 2017, BD completed the acquisition of Israeli-based Caesarea Medical Electronics (CME), a global infusion pump systems manufacturer. In March 2014, CareFusion Corp., which was acquired by BD in 2015, had acquired a non-controlling, minority stake in CME. The acquisition of CME expanded BD’s infusion portfolio to include ambulatory, home, and specialty acute care infusion pumps.
About Becton Dickinson & Co.
Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD is a global medical technology Company that is advancing the world of health by improving medical discovery, diagnostics, and delivery of care. The Company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes.
About C. R. Bard, Inc.
Established in 1907, Bard is a leading multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of Vascular, Urology, Oncology, and Surgical Specialties. The Company is based in Murray Hill, New Jersey.
Stock Performance Snapshot
January 02, 2018 - At Tuesday’s closing bell, Becton Dickinson’s stock advanced 1.77%, ending the trading session at $217.84.
Volume traded for the day: 2.69 million shares, which was above the 3-month average volume of 1.23 million shares.
Stock performance in the last three-month — up 10.98%; previous six-month period — up 11.93%; past twelve-month period — up 31.59%; and year-to-date - up 1.77%
After yesterday’s close, Becton Dickinson’s market cap was at $50.04 billion.
Price to Earnings (P/E) ratio was at 46.83.
The stock has a dividend yield of 1.38%.
The stock is part of the Healthcare sector, categorized under the Medical Instruments & Supplies industry. This sector was up 1.4% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors